Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.53 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14544143 | 0.86 | FFAR1 (0.52) | S1PR1S1PR3S1PR5FFAR1NR1H4 | |
| SCHEMBL13979619 | 0.86 | FFAR1 (0.52) | S1PR1S1PR3S1PR5FFAR1NR1H4 | |
| SCHEMBL14544145 | 0.85 | FFAR1 (0.53) | S1PR1S1PR3S1PR5FFAR1NR1H4 | |
| SCHEMBL4657948 | 0.81 | S1PR1 (0.55) | S1PR1S1PR3S1PR5FFAR1NR1H4 | |
| SCHEMBL13979618 | 0.81 | RAB9A (0.48) | NR1H4KMT2ALTA4HMEN1 | |
| SCHEMBL12688084 | 0.80 | FFAR1 (0.65) | S1PR1S1PR3S1PR5FFAR1PLA2G4B | |
| SCHEMBL4657192 | 0.80 | S1PR1 (0.58) | S1PR1S1PR3S1PR5FFAR1NR1H4 | |
| SCHEMBL14544244 | 0.79 | RAB9A (0.48) | S1PR1NR1H4KMT2ALTA4HMEN1 | |
| SCHEMBL14544256 | 0.79 | FFAR1 (0.68) | S1PR1S1PR3S1PR5FFAR1PLA2G4B | |
| SCHEMBL13979610 | 0.79 | FFAR1 (0.50) | S1PR1S1PR3S1PR5FFAR1NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1391199-B1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2007-04-19 | — | — | US | disclosed |
| US-7179817-B2 | Carboxylic acid derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088027-A1 | Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient | EDF1, FFAR1, EDNRA | S1PR1 405/4885S1PR3 1027/4885S1PR5 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.